Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Finished Goods (2016 - 2018)

Apyx Medical filings provide 3 years of Finished Goods readings, the most recent being $1.1 million for Q4 2018.

  • On a quarterly basis, Finished Goods rose 10.35% to $1.1 million in Q4 2018 year-over-year; TTM through Dec 2018 was $1.1 million, a 10.35% increase, with the full-year FY2018 number at $1.1 million, up 10.35% from a year prior.
  • Finished Goods hit $1.1 million in Q4 2018 for Apyx Medical, up from $1.0 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $3.0 million in Q4 2016 to a low of $1.0 million in Q4 2017.
  • Median Finished Goods over the past 3 years was $1.1 million (2018), compared with a mean of $1.7 million.
  • Biggest five-year swings in Finished Goods: plummeted 66.4% in 2017 and later rose 10.35% in 2018.
  • Apyx Medical's Finished Goods stood at $3.0 million in 2016, then plummeted by 66.4% to $1.0 million in 2017, then rose by 10.35% to $1.1 million in 2018.
  • The last three reported values for Finished Goods were $1.1 million (Q4 2018), $1.0 million (Q4 2017), and $3.0 million (Q4 2016) per Business Quant data.